中国药房2026，Vol.37Issue(16)：2150-2155,6.DOI:10.6039/j.issn.1001-0408.2026.16.12
美泊利珠单抗用于嗜酸粒细胞性慢性鼻窦炎伴鼻息肉鼻内窥镜手术后维持治疗的效果分析
Analysis of the efficacy of mepolizumab for maintenance therapy following endoscopic sinus surgery in patients with eosinophilic chronic rhinosinusitis with nasal polyps
摘要
Abstract
OBJECTIVE To investigate the clinical efficacy of mepolizumab as postoperative maintenance therapy after endoscopic sinus surgery(ESS)in patients with eosinophilic chronic rhinosinusitis with nasal polyps(EosCRSwNP).METHODS A retrospective cohort study was conducted to collect clinical data from patients with EosCRSwNP who underwent ESS at the Dept.of Otolaryngology in Xuzhou First People's Hospital,from January 1 to May 31,2025.Patients were divided into a control group(56 cases,treated with intranasal corticosteroids postoperatively)and an observation group(51 cases,treated with mepolizumab postoperatively)based on their postoperative maintenance therapy regimens.The nasal function parameters[nasal cavity volume(NCV),distance from the minimum cross-sectional area to the anterior nostril(DCAN),nasal minimum cross-sectional area(NMCA),saccharin clearance time,nasal mucociliary clearance rate,mucociliary clearance velocity],and the indicators related to nasal mucosal remodeling[peripheral blood eosinophil(EOS)percentage,serum levels of transforming growth factor-β1(TGF-β1)and vascular endothelial growth factor(VEGF)]were compared between the two groups at 2 weeks and 3,6 months after surgery.The assessment indicators of the inflammation status of nasal mucositis[modified Lund-Kennedy Endoscopic Scoring System(MLK)score],the degree of nasal polyp recurrence[nasal polyp score(NPS)],and the quality of life[Sino-nasal Outcome Test-20(SNOT-20)score]were compared at 2 weeks and 6 months after surgery.Adverse events were also recorded and compared between the two groups.RESULTS At 2 weeks after surgery,there were no statistically significant differences in the aforementioned indicators/scores between the two groups(P＞0.05).Compared with the same group at 2 weeks postoperatively,both groups showed significant increases in NCV,NMCA,nasal mucociliary clearance rate,and mucociliary clearance velocity at 3 and 6 months postoperatively;significant decreases or reductions were observed in DCAN,saccharin clearance time,EOS percentage,TGF-β1 and VEGF levels at 3 and 6 months postoperatively,while in MLK score,NPS,SNOT-20 score were all significantly reduced or shortened(P＜0.05).Furthermore,the improvements in these indicators in the observation group were significantly greater than those in the control group during the same time periods(P＜0.05).The overall incidence of adverse reactions was comparable between the two groups(P＞0.05),but the incidence of injection-site reactions was significantly higher in the observation group than in the control group(P＜0.05).CONCLUSIONS The use of mepolizumab for postoperative maintenance therapy following ESS in patients with EosCRSwNP promotes the recovery of nasal function,improves indicators of nasal mucosal remodeling,reduces inflammation,lowers polyp score,and enhances quality of life.Its efficacy is superior to that of intranasal corticosteroids;however,clinicians should be mindful of the risk of injection-site reactions of mepolizumab.关键词
美泊利珠单抗/嗜酸粒细胞性鼻窦炎伴鼻息肉/鼻内镜手术/术后维持治疗Key words
mepolizumab/eosinophilic chronic rhinosinusitis with nasal polyps/endoscopic sinus surgery/postoperative maintenance therapy分类
医药卫生引用本文复制引用
丁锐,陈力,蔡博宇,梁言..美泊利珠单抗用于嗜酸粒细胞性慢性鼻窦炎伴鼻息肉鼻内窥镜手术后维持治疗的效果分析[J].中国药房,2026,37(16):2150-2155,6.基金项目
国家自然科学基金项目(No.82501374) （No.82501374）
